Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Gavere – page 27

1 677 clinical trials in Gavere, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gavere at a glance
1 677
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 677 trials in Gavere

Open in trial search

Study of cefadroxil effectiveness in adult patients with Staphylococcus aureus bloodstream infection

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cefadroxil
  • Sponsor:UZ Brussel

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Janssen Cilag International

Evaluation of SB-007 Safety and Efficacy in Patients with Stargardt Disease Type 1 (STGD1) Caused by ABCA4 Gene Mutations

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:AAV-ABCA4-Int-C
  • Sponsor:Splicebio S.L.

Evaluating NBI-1065845 as an Additional Treatment for Adults with Major Depressive Disorder Who Are Not Responding Adequately to Current Therapy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Osavampator
  • Sponsor:Neurocrine Biosciences Inc.

Neuroblastoma

Recruiting

Study of Temozolomide, Topotecan, Bevacizumab, Irinotecan and Dinutuximab Beta in Patients with High-Risk Relapsed Neuroblastoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Bevacizumab
  • Sponsor:The University Of Birmingham

Study of Trastuzumab Deruxtecan, Rilvegostomig, and Pembrolizumab for Advanced or Recurrent Endometrial Cancer in HER2-Positive Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study of Seladelpar Treatment in Patients with Primary Biliary Cholangitis and Compensated Cirrhosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Seladelpar
  • Sponsor:Gilead Sciences Inc.

Study of Sigvotatug Vedotin and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Pfizer Inc.

Study on Ovarian Stimulation Using Follitropin Delta and Dydrogesterone for Women Donating Eggs

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:Dydrogesterone
  • Sponsor:UZ Brussel

Study of DNTH103 Treatment for Adults with Chronic Inflammatory Demyelinating Polyneuropathy: Comparing Effectiveness with Placebo

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:DNTH103
  • Sponsor:Dianthus Therapeutics Inc.

Study on Immune Response Differences to Meningococcal Group B Vaccine in Healthy Transgender and Cisgender Adults Aged 18-40

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:Outer Membrane Vesicles (Omv) From Neisseria Meningitidis Group B Strain Nz98/254 Measured As Amount Of Total Protein Containing The Pora P1.4 Adsorbed On Aluminium Hydroxide
  • Sponsor:Universiteit Gent

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Gavere

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on proton pump inhibitor (PPI) medication management and deprescribing strategies for patients with chronic gastrointestinal conditions.

  • Functional Dyspepsia Management
  • Heartburn Treatment Optimization
  • Reflux Therapy Alternatives

This primary care-based trial evaluates different approaches to reducing long-term PPI use, including on-demand therapy and alternative treatments with alginate formulations, aiming to establish optimal deprescribing protocols.

02 Primary Care Innovation

Ground-breaking research exploring patient-centered approaches to medication reduction in primary care settings, with a focus on chronic medication management.

  • Medication Optimization
  • Patient-Centered Care
  • Evidence-Based Deprescribing

The study compares different therapeutic strategies to help patients safely reduce their dependence on long-term acid suppression medication.

03 Therapeutic Strategy Comparison

Comprehensive evaluation of three distinct approaches to medication deprescribing, focusing on long-term outcomes and patient safety.

  • Comparative Effectiveness Research
  • Alternative Treatment Methods
  • Safety Monitoring

This research aims to establish evidence-based guidelines for reducing unnecessary long-term medication use while maintaining symptom control.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.